目的 研究灯盏生脉胶囊联合盐酸替罗非班注射液治疗冠心病心绞痛的临床疗效。方法 选取2015年6月-2017年6月榆林市第一医院接收的冠心病心绞痛患者120例为研究对象，将所有患者随机分为对照组和治疗组，每组各60例。对照组患者给予盐酸替罗非班注射液，初始以10 μg/kg进行静脉推注，3 min内完成，之后以0.15 μg/（kg·min）维持滴注。治疗组患者在对照组治疗的基础上口服灯盏生脉胶囊，3粒/次，3次/d。两组患者持续治疗2周。观察两组的临床疗效和心电图疗效，比较两组的临床症状、血清细胞因子水平。结果 治疗后，对照组和治疗组的总有效率分别为81.67%、96.67%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的心电图疗效总有效率分别为81.67%、96.67%，两组比较差异有统计学意义（P<0.05）。治疗后，两组心绞痛发作次数和心绞痛持续时间显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组TNF-α和IL-6均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 灯盏生脉胶囊联合盐酸替罗非班注射液治疗冠心病心绞痛具有较好的临床疗效，可改善患者临床症状，调节血清细胞因子水平，安全性较高，具有一定的临床推广应用价值。

Objective To study the effect of Dengzhan Shengmai Capsules combined with Tirofiban Hydrochloride Injection in treatment of angina pectoris of coronary heart disease. Methods Patients (120 cases) with angina pectoris of coronary heart disease in the First Hospital of Yulin from June 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given Tirofiban Hydrochloride Injection, initial intravenous injection with 10 μg/kg, and completed within 3 min, then continuous iv administered with dosage of 0.15 μg/(kg·min). Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies and electrocardiogram efficacies were evaluated, and clinical symptoms and serum cytokine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 96.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 81.67% and 96.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Dengzhan Shengmai Capsules combined with Tirofiban Hydrochloride Injection has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve clinical symptoms, regulate serum cytokines levels, with good safety, which has a certain clinical application value.